Similarly, small-molecule inhibitors of Dbr1 may also find utility in the treatment of neurodegenerative diseases, such as ALS and FTLD, where partial inhibition of Dbr1 allows accumulation of lariat RNAs to sequester toxic forms of the RNA-binding TDP-43 protein (18). Here, TARDBP is linked to neurodegenerative disease.